The Phase Ib/II trial assessed evorpacept plus zanidatamab in previously treated, metastatic HER2-expressing cancers.
“High-sensitivity CRP has been shown to be an independent marker of risk in addition to and in some cases over and above all other risk factors that we typically talk about including smoking, diabetes ...
Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising ...
In the era of personalized oncology, implementation of reliable biomarkers with prognostic and predictive value is necessary, the latter being most ...
Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ...
Predictive Oncology Inc. has updated shareholders on its advancements in AI-driven drug discovery, specifically in biomarker discovery and drug repurposing, amid a growing biomarker discovery market ...
D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory ...
Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted ...
The integration of PD-1 inhibitors into standard chemotherapy and radiotherapy regimens has revolutionized nasopharyngeal carcinoma treatment, yet only a minority of patients achieve durable responses ...
Particle therapy, including proton and carbon ion radiotherapy, represents a major advancement in cancer treatment due to its ...
—Using multimodal imaging, this 10-year prospective cohort study identified markers that could help stratify patients at high risk of progressing to advanced AMD, which may help inform clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results